Destiny Pharma – Secondary endpoint analysis from Phase 2b trial
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused … Continue reading “Destiny Pharma – Secondary endpoint analysis from Phase 2b trial”
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused … Continue reading “Destiny Pharma – Secondary endpoint analysis from Phase 2b trial”
Presenting at The Peter Davies Memorial Symposium: The Future of Tau Based … Continue reading “Asceneuron CEO Dirk Beher to speak at Alzheimer’s Association International Conference”
Plans to initiate a pivotal trial for patients suffering from Tenosynovial Giant … Continue reading “SynOx Therapeutics Strengthens Team with appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer”
Financing to amplify the scale and impact of Genomatica’s sustainable materials Underscores … Continue reading “Novo Holdings Leads US$ 118M Series C Investment in Genomatica”
• Funding propels Artios’ ability to progress beyond synthetic lethality and to continue … Continue reading “Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X”
eTheRNA immunotherapies NV (‘eTheRNA’ or the ‘Company’), a clinical-stage company developing mRNA-based … Continue reading “eTheRNA immunotherapies appoints Mathieu Lane as Chief Financial Officer and President of eTheRNA Inc. located in the U.S.A.”
Copenhagen, Denmark and Boston, US – 22 July 2021 Hemab ApS (“Hemab”), … Continue reading “Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders”
Novo Holdings created Hemab from inception and now co-leads significant financing with … Continue reading “Novo Holdings co-leads Hemab’s US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders”
Calliditas and STADA partner to bring a specialty therapy focused on downregulating … Continue reading “Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe”
Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus … Continue reading “ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline”
Lausanne, SWITZERLAND and San Francisco, CA, USA, 16 July 2021 – Asceneuron SA, … Continue reading “Asceneuron Appoints Prominent Healthcare Leader Catherine Moukheibir to its Board of Directors”
Brings substantial industry expertise and strategic focus for sustained company development. Copenhagen, … Continue reading “Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors”
Accelerated clinical development of ExeVir’s novel llama-derived antibody therapies for potential treatment … Continue reading “ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments (EN/FR/NL)”
Oegstgeest, 13 July 2021, ISA announces the closing of a EUR 26 million … Continue reading “ISA announces successful closing of EUR 26 million funding round”
Novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety and … Continue reading “eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement”
Data illustrates potent neutralization activity against the Gamma and Delta Variants of … Continue reading “ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern (EN/FR/NL)”
Successful XF-73 nasal gel Phase 2b study data to be presented at … Continue reading “Destiny Pharma plc – XF-73 Phase 2b data to be presented at ECCMID”
Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia … Continue reading “Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases”
Micropep technologies (Micropep) has raised EUR 8.5 million (USD 10 million) in … Continue reading “Micropep Raises 8.5M€ in oversubscribed Series A Financing to develop innovative small peptide solutions for agriculture”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
